Pain syndromes in endometriosis: an integrated approach to the problem management

T. Tatarchuk
{"title":"Pain syndromes in endometriosis: an integrated approach to the problem management","authors":"T. Tatarchuk","doi":"10.32902/2663-0338-2020-3.2-271-273","DOIUrl":null,"url":null,"abstract":"Background. Endometriosis affects 10 % of women of reproductive age. Endometriosis is often accompanied by the following symptoms: dyspareunia, pelvic pain, and dysmenorrhea. Pain is a leading symptom of endometriosis and often persists despite treatment. \nObjective. To elucidate the basics of pathogenesis and treatment of pain in endometriosis. \nMaterials and methods. Analysis of literature data on this topic; own study involving 64 women with endometriosis. Group 1 was given dienogest (2 mg per day) for 3 months, and group 2 was given dienogest in combination with Tivortin (5 intravenous infusions of 100 ml each other day with the switch to Tivortin aspartate (“Yuria-Pharm”) orally). \nResults and discussion. Pain in endometriosis includes several pathophysiological mechanisms: increased nociception, inflammation, and changes in the recognition of pain in the nervous system. Significant pelvic vascularization promotes the rapid transmission of pain signals from this area to the brain. The severity of pain noted by women poorly correlates with the degree of disease detected during surgery. According to the recommendations of NICE (2017), one or more of the following symptoms are sufficient for suspected endometriosis: chronic pelvic pain (>6 months), dysmenorrhea, which adversely affects quality of life and daily activity, dyspareunia, gastrointestinal disorders and urinary system symptoms associated with menstruation, and infertility in combination with one or more of the above symptoms. Endometriosis requires flexible adaptation of management and the constant choice of treatment tactics depending on the symptoms and life situation of the patient. The basic goals of treatment inlude elimination of symptoms, restoration of quality of life and fertility, prevention of recurrences and repeated surgical intervention. Analgesics, neuromodulators and hormonal agents are used for pharmacological pain management. Additional and alternative methods include reflexology, manual therapy, osteopathy, exercise, dietary changes, and sleep hygiene. Elimination of the oxidation imbalance is one of the methods to treat pain in endometriosis. The uterus is a highly vascularized organ and its cells are constantly affected by high concentrations of oxygen. In settings of hypoxia, steroidogenesis, angiogenesis, inflammation and metabolic transition occur in endometrial cells. In women with endometriosis, there is an increase in markers of oxidative stress in the blood. Intrauterine oxidative stress can be eliminated with the powerful antioxidant L-arginine (Tivortin, “Yuria-Pharm”). In our own study, it was shown that the inclusion of Tivortin into the treatment allowed to decrease the intensity of intermenstrual endometriosis-associated pelvic pain more markedly than the standard treatment. The initial pain level was 61.32±3.2 according to the visual-analog scale in group 1 and 64.2±2.8 in group 2 (Tivortin). A month later, the indicators were 36.5±2.6 and 27.2±2.2, respectively. It should be noted that the effect of Tivortin is stable. In the standard treatment group, the intensity of pain increased again after the end of therapy, and in the Tivortin group remained at a low level. Evaluation of the McGill questionnaire results showed that in Tivortin group pain decreased not only due to the actual strength of the pain, but also due to a decrease in its sensory and emotional characteristics. After treatment, in group 1 the intensity of menstrual bleeding also increased more markedly. \nConclusions. 1. The goals of endometriosis treatment are to eliminate symptoms, restore quality of life and fertility, prevent recurrence and repeated surgeries. 2. The effectiveness of L-arginine (Tivortin) in the treatment of endometriosis was ensured by normalizing vascular tone in the pelvic organs, reducing oxidative stress, psychostabilizing effect, increasing the antibacterial activity of neutrophils. 3. The use of Tivortin is a promising area for the treatment of endometriosis and prevention of its recurrence.","PeriodicalId":13681,"journal":{"name":"Infusion & Chemotherapy","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infusion & Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32902/2663-0338-2020-3.2-271-273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Endometriosis affects 10 % of women of reproductive age. Endometriosis is often accompanied by the following symptoms: dyspareunia, pelvic pain, and dysmenorrhea. Pain is a leading symptom of endometriosis and often persists despite treatment. Objective. To elucidate the basics of pathogenesis and treatment of pain in endometriosis. Materials and methods. Analysis of literature data on this topic; own study involving 64 women with endometriosis. Group 1 was given dienogest (2 mg per day) for 3 months, and group 2 was given dienogest in combination with Tivortin (5 intravenous infusions of 100 ml each other day with the switch to Tivortin aspartate (“Yuria-Pharm”) orally). Results and discussion. Pain in endometriosis includes several pathophysiological mechanisms: increased nociception, inflammation, and changes in the recognition of pain in the nervous system. Significant pelvic vascularization promotes the rapid transmission of pain signals from this area to the brain. The severity of pain noted by women poorly correlates with the degree of disease detected during surgery. According to the recommendations of NICE (2017), one or more of the following symptoms are sufficient for suspected endometriosis: chronic pelvic pain (>6 months), dysmenorrhea, which adversely affects quality of life and daily activity, dyspareunia, gastrointestinal disorders and urinary system symptoms associated with menstruation, and infertility in combination with one or more of the above symptoms. Endometriosis requires flexible adaptation of management and the constant choice of treatment tactics depending on the symptoms and life situation of the patient. The basic goals of treatment inlude elimination of symptoms, restoration of quality of life and fertility, prevention of recurrences and repeated surgical intervention. Analgesics, neuromodulators and hormonal agents are used for pharmacological pain management. Additional and alternative methods include reflexology, manual therapy, osteopathy, exercise, dietary changes, and sleep hygiene. Elimination of the oxidation imbalance is one of the methods to treat pain in endometriosis. The uterus is a highly vascularized organ and its cells are constantly affected by high concentrations of oxygen. In settings of hypoxia, steroidogenesis, angiogenesis, inflammation and metabolic transition occur in endometrial cells. In women with endometriosis, there is an increase in markers of oxidative stress in the blood. Intrauterine oxidative stress can be eliminated with the powerful antioxidant L-arginine (Tivortin, “Yuria-Pharm”). In our own study, it was shown that the inclusion of Tivortin into the treatment allowed to decrease the intensity of intermenstrual endometriosis-associated pelvic pain more markedly than the standard treatment. The initial pain level was 61.32±3.2 according to the visual-analog scale in group 1 and 64.2±2.8 in group 2 (Tivortin). A month later, the indicators were 36.5±2.6 and 27.2±2.2, respectively. It should be noted that the effect of Tivortin is stable. In the standard treatment group, the intensity of pain increased again after the end of therapy, and in the Tivortin group remained at a low level. Evaluation of the McGill questionnaire results showed that in Tivortin group pain decreased not only due to the actual strength of the pain, but also due to a decrease in its sensory and emotional characteristics. After treatment, in group 1 the intensity of menstrual bleeding also increased more markedly. Conclusions. 1. The goals of endometriosis treatment are to eliminate symptoms, restore quality of life and fertility, prevent recurrence and repeated surgeries. 2. The effectiveness of L-arginine (Tivortin) in the treatment of endometriosis was ensured by normalizing vascular tone in the pelvic organs, reducing oxidative stress, psychostabilizing effect, increasing the antibacterial activity of neutrophils. 3. The use of Tivortin is a promising area for the treatment of endometriosis and prevention of its recurrence.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
子宫内膜异位症的疼痛综合征:问题管理的综合方法
背景。子宫内膜异位症影响10%的育龄妇女。子宫内膜异位症常伴有以下症状:性交困难、盆腔疼痛和痛经。疼痛是子宫内膜异位症的主要症状,尽管治疗,疼痛仍然存在。目标。目的:探讨子宫内膜异位症疼痛的发病机制及治疗方法。材料和方法。本课题的文献资料分析;对64名患有子宫内膜异位症的女性的研究。组1给予地诺孕素(2 mg / d),连用3个月;组2给予地诺孕素联合替沃汀(5次静脉滴注,每隔一天100 ml,切换为天冬氨酸替沃汀(“Yuria-Pharm”)口服)。结果和讨论。子宫内膜异位症的疼痛包括几种病理生理机制:痛觉增加、炎症和神经系统对疼痛识别的改变。明显的骨盆血管形成促进疼痛信号从该区域快速传递到大脑。妇女注意到的疼痛严重程度与手术中发现的疾病程度相关性不大。根据NICE(2017)的建议,以下一种或多种症状足以诊断疑似子宫内膜异位症:慢性盆腔疼痛(>6个月)、对生活质量和日常活动产生不利影响的痛经、性交困难、与月经相关的胃肠道疾病和泌尿系统症状,以及合并上述一种或多种症状的不孕症。子宫内膜异位症需要根据患者的症状和生活状况灵活适应治疗和不断选择治疗策略。治疗的基本目标包括消除症状,恢复生活质量和生育能力,预防复发和反复手术干预。镇痛药,神经调节剂和激素制剂用于药物疼痛管理。其他替代方法包括反射疗法、手工疗法、整骨疗法、运动、饮食改变和睡眠卫生。消除氧化失衡是治疗子宫内膜异位症疼痛的方法之一。子宫是一个高度血管化的器官,其细胞经常受到高浓度氧气的影响。在缺氧的情况下,子宫内膜细胞会发生类固醇生成、血管生成、炎症和代谢转变。在患有子宫内膜异位症的女性中,血液中的氧化应激标志物增加。宫内氧化应激可以通过强大的抗氧化剂l -精氨酸(Tivortin,“Yuria-Pharm”)消除。在我们自己的研究中,研究表明,与标准治疗相比,将Tivortin纳入治疗可以更显著地降低月经期间子宫内膜异位症相关盆腔疼痛的强度。根据视觉模拟量表,1组患者初始疼痛水平为61.32±3.2,2组患者初始疼痛水平为64.2±2.8 (Tivortin)。1个月后,各指标分别为36.5±2.6和27.2±2.2。值得注意的是,替沃汀的效果是稳定的。标准治疗组疼痛强度在治疗结束后再次升高,而Tivortin组疼痛强度维持在较低水平。对McGill问卷结果的评估显示,在Tivortin组中,疼痛不仅由于疼痛的实际强度而减轻,而且由于其感觉和情绪特征的减少。治疗后,1组月经出血强度明显增加。结论:1。子宫内膜异位症治疗的目标是消除症状,恢复生活质量和生育能力,防止复发和重复手术。2. l -精氨酸(Tivortin)治疗子宫内膜异位症的有效性是通过使盆腔器官血管张力正常化,减少氧化应激,精神稳定作用,增加中性粒细胞的抗菌活性来保证的。3.替沃汀是治疗子宫内膜异位症和预防其复发的一个有前途的领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Evaluation of the effectiveness of immunomodulator BI-V in the complex therapy of children and adolescents with multiple drug-resistant pulmonary tuberculosis Features of the course of pulmonary tuberculosis against the background of coronavirus infection according to computed tomography of the chest organs Risks of recurrence in people with pulmonary tuberculosis New and little-known possibilities of edaravone in the treatment of cerebral stroke and extracranial pathology Severe community-acquired pneumonia: principles of diagnostics and intensive therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1